Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy

WangZ.; HuangH.

首页> 外文期刊>Cancer letters >Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy

【24h】

Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy

机译：血小板因子4（CXCL4 / PF-4）：用于癌症治疗的血管抑制趋化因子

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Platelet factor-4 (CXCL4/PF-4) is the first chemokine identified to have several biological functions. Notably, CXCL4/PF-4 inhibits endothelial cell proliferation and migration, leading to suppression of angiogenesis. Since angiogenesis is essential for the growth of most primary tumors and their subsequent metastases, it is a target for cancer therapy; due to its multiple functions, CXCL4/PF-4 is a potential clinical anti-tumor agent. This report reviews the mechanisms of CXCL4/PF-4 angiostatic activity, including interference with angiogenic growth factors bFGF-2 and VEGF165, activation of CXCR3B, interactions with integrins, interference with cell cycle, interactions with factors such as VEGF121 and CXCL8/IL-8, and derived molecules of CXCL4/PF-4 with angiostatic and anti-tumoral activities in different models in vivo or in vitro.

机译：血小板因子4（CXCL4 / PF-4）是第一个被鉴定具有多种生物学功能的趋化因子。值得注意的是，CXCL4 / PF-4抑制内皮细胞增殖和迁移，从而抑制血管生成。由于血管生成对于大多数原发性肿瘤及其后续转移的生长至关重要，因此它是癌症治疗的目标。由于其多种功能，CXCL4 / PF-4是潜在的临床抗肿瘤药物。该报告综述了CXCL4 / PF-4血管抑制活性的机制，包括干扰血管生成生长因子bFGF-2和VEGF165，激活CXCR3B，与整联蛋白相互作用，干扰细胞周期，与诸如VEGF121和CXCL8 / IL-的相互作用。参见图8，并且在体内或体外的不同模型中衍生的具有血管生成和抗肿瘤活性的CXCL4 / PF-4分子。

著录项

来源
《Cancer letters》 |2013年第2期|共7页
作者
WangZ.; HuangH.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Angiogenesis; Cancer therapy; Platelet factor-4;

机译：血管生成;癌症治疗;血小板因子4;

相似文献

外文文献
中文文献
专利

1. Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy [J] . WangZ., HuangH. Cancer letters . 2013,第2期

机译：血小板因子4（CXCL4 / PF-4）：用于癌症治疗的血管抑制趋化因子
2. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor [J] . David J.Auerbach, Yin Lin, Huiyi Miao, Proceedings of the National Academy of Sciences of the United States of America . 2012,第24期

机译：鉴定血小板衍生的趋化因子CXCL4 / PF-4作为广谱HIV-1抑制剂
3. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. [J] . Struyf S, Salogni L, Burdick MD, Blood: The Journal of the American Society of Hematology . 2011,第2期

机译：CXC趋化因子CXCL4L1（血小板因子4变体）的血管抑制和趋化活性由CXCR3介导。
4. Designing a C-X-C Motif Chemokine 12 Based Decoy Protein for Cancer Therapy [C] . Martha Gschwtner, Martin U. Trinker, Bianca Hecher, PEGS . 2015

机译：设计基于C-X-C主题趋化因子的癌症治疗诱饵蛋白
5. CXCR3 and its cognate-chemokine expression: implications for cancer immunotherapy. [D] . Clancy-Thompson, Eleanor. 2015

机译：CXCR3及其同源趋化因子表达：对癌症免疫治疗的意义。
6. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor [O] . David J. Auerbach, Yin Lin, Huiyi Miao, 2012

机译：鉴定血小板衍生的趋化因子CXCL4 / PF-4作为广谱HIV-1抑制剂
7. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis [O] . Struyf, Sofie, Burdick, Marie D, Proost, Paul, 2004

机译：血小板释放CXCL4L1，它是趋化因子血小板因子4 / CXCL4的非等位变体，是血管新生的有效抑制剂
8. Angiostatic Therapy: A New Treatment Modality for Prostate Cancer. [R] . Borgstrom, P. 2001

机译：血管抑制治疗：前列腺癌的新治疗方式。

Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy

摘要

著录项

相似文献

相关主题

期刊订阅